Radiation Protection in Radiotherapy - PowerPoint PPT Presentation

1 / 52
About This Presentation
Title:

Radiation Protection in Radiotherapy

Description:

EBT (45Gy) Implant Boost. Seed Implant (108Gy) HDR Implant (16.5Gy/3) ... the critical cold spots can be boosted by either placing more seeds in the ... – PowerPoint PPT presentation

Number of Views:231
Avg rating:3.0/5.0
Slides: 53
Provided by: iaea
Category:

less

Transcript and Presenter's Notes

Title: Radiation Protection in Radiotherapy


1
Radiation Protection inRadiotherapy
IAEA Training Material on Radiation Protection in
Radiotherapy
  • Part 6
  • Brachytherapy
  • Lecture 2 (cont.) Brachytherapy Techniques

2
Brachytherapy
  • Very flexible radiotherapy delivery
  • Allows a variety of different approaches,
    creating the opportunity for special and highly
    customized techniques
  • Not only used for malignant disease (cancer)

3
Special techniques
  • A. Prostate seed implants
  • B. Endovascular brachytherapy
  • C. Ophthalmic applicators
  • D. Other special techniques

Both point B and C are examples for the use of
brachytherapy for non-oncological purposes
4
A. 125-I seeds for prostate implants
  • Relatively new technique
  • Indicated for localized early stage prostate
    cancer
  • Permanent implant
  • Preferred by many patients as it only requires
    one day in hospital

5
Treatment Options for prostate cancer
  • Seed Implant Monotherapy (about 144Gy)
  • EBT (45Gy) Implant Boost
  • Seed Implant (108Gy)
  • HDR Implant (16.5Gy/3)
  • External Beam only (65-84Gy)
  • Surgery (Radical Prostatectomy)
  • This all could be combined with hormones and/or
    chemotherapy

6
Implant schematic
7
A typical implant
  • Deliver 144 Gy to entire prostate gland
  • Approximately 100 I-125 seeds (25 needles)
  • Needles are guided by ultrasound and a template
    grid
  • Pre-planned needle positions to give even dose
    but avoid pubic arch
  • Minimise rectal dose and avoid urethra overdose
  • CT after 3 weeks for post-planning

8
Isotopes in use
  • Iodine 125 - 144Gy - I-125
  • Half Life 60 days
  • Energy 28 keV
  • TVL lead 0.08mm
  • Palladium 103 - 108Gy - Pd -103
  • Half Life 17 days - dose rate about 2.5 times
    larger than for 125-I
  • Energy 22 keV
  • TVL lead 0.05mm

9
Prostate Implant Process
  • Ultrasound Volume Study
  • Pre-planning what would be ideal
  • Ordering I-125 seeds and calibration
  • Needle loading
  • Ultrasound guided Implantation
  • CT post-planning a couple of weeks after what
    has been achieved?

10
Patient flow in brachytherapy
Treatment decision
Ideal plan - determines source number and location
Implant of sources or applicators in theatre
Localization of sources or applicators (typically
using X Rays)
Treatment plan
Commence treatment
11
Pre-planning
  • Several different systems possible
  • Provides guidance for approach, data on number of
    sources required and loading of needles
  • Avoid central column to spare urethra
  • Cover target laterally
  • Conform to posterior border (spare rectum)

12
Preparation of seeds
  • Ordering planned number of seeds some spares
  • Checking seed activity
  • Sorting and loading seeds into needles

Seed alignment tray
13
Implant needle loaded with seeds and spacers
14
Implant template
15
Implant jig
16
Ultrasound Guided Implant Procedure
17
X-ray of implanted seed
18
CT post-planning after 4 weeks
Swelling is gone - CT provides true three
dimensional information on the implant geometry
19
Post CT planning establishing the actual dose
distribution
20
Patient flow in brachytherapy
Treatment decision
Ideal plan - determines source number and location
Implant of sources or applicators in theatre
Localization of sources or applicators (typically
using X Rays)
Treatment plan
Commence treatment
21
Quality of Implant
  • Depends on seed placement
  • Seeds may migrate with time
  • If large dose inhomogeneities exist, the critical
    cold spots can be boosted by either placing more
    seeds in the prostate or using external beam
    radiotherapy

22
Notes on prostate seed implants
  • A similar technique is available using 103-Pd
    seeds
  • 103-Pd has a shorter half life and therefore a
    higher activity is implanted
  • Otherwise the rules an considerations are similar
    to 125-I seed implants

23
2. Endovascular brachytherapy
24
The issue re-stenosis
  • After opening of a blocked blood vessel there is
    a high (60) likelihood that the vessel is
    blocked again Re-stenosis
  • Radiation is a proven agent to prevent growth of
    cells
  • Radiation has been shown to be effective in
    preventing re-stenosis

25
Dilation of blood vessels
  • Mostly for cardiac vessels but also possible in
    some extremities

26
Endovascular irradiation
  • Mostly for cardiac vessels but also possible in
    some extremities
  • Many different systems and isotopes in use

27
Isotopes for endovascular brachytherapy
  • Gamma sources 192-Ir
  • the first source which has been clinically used
    (Terstein et al. N Eng J Med 1996)
  • Beta sources 32-P, 90-Sr/Y, 188-Rh (Rhenium)
  • Activity around 1Ci

Dose calculation
28
Beta sources
  • Most commercial systems use them because
  • finite range in tissues
  • less radiation safety issues in the operating
    theatre
  • smaller, hand held units possible for use in
    cardiac theatres
  • Potential problem may not reach all cells of
    interest

29
The Beta-Cath System (Novoste)
30
Guidant system
  • Employs centering catheter to ensure source is
    always in the center of the vessel

31
Radiation safety in theatre
  • Application of radiation in theatre
  • time is of the essence - planning in situ
  • shielding would be difficult
  • physicists must be present

32
Irradiation of extended lesions
  • Use Radiation Source Train
  • Stepping source process to cover desired length

100
Longitudinal Dose Distribution
50
0
L/2
L/2
33
Angiographic Appearance of PDL in Delivery
Catheter
34
Radiation Source Train Dose Profile at 2mm
40mm Radiation Source Train (RST)
35
Radioactive stents
  • Stents are used to keep blood vessels open
  • Can be impregnated with radioactive material
    (typically 32-P) to help prevention of re-stenosis

36
C. Ophthalmic applicators
  • Treatment of pterigiums and corneal vasculations,
    a non-oncological application of radiotherapy
  • Use of beta sources - mostly 90-Sr/Y
  • Typical activity 40 to 200MBq (10-50mCi)

37
Ophthalmic applicators
  • Activity covered by thin plated gold or platinum
  • Curvature to fit the ball of the eye
  • Diameter 12 to 18mm
  • Activity may only be applied to parts of the
    applicator
  • Typical treatment time for several Gy less than
    1min

38
Decay scheme of 90Sr / 90Y
90Sr
ß 0.54 MeV, T1/2 28.5 yrs
90Y
ß 2.25 MeV, T1/2 64 hrs
90Zr
39
Dept Dose Curve of 90Sr in H2O
Finite treatment depth
40
Issues with ophthalmic applicators - dosimetry
  • Dosimetry difficult due to short range of
    particles
  • Dose uncertainty gt 10
  • Short treatment times taken from look-up tables -
    potential for mistakes
  • Documentation often less than complete

41
Other guidance and issues
  • Never point source at someone - range in tissue
    lt1cm, but in air gt 1m!!!
  • Radiation typically used by non radiotherapy
    staff (eye specialists, nurses) - training
    required
  • Sterilisation/cleaning - must not affect
    integrity of the cover
  • Regular check of homogenous distribution of
    activity required
  • Wipe tests required

42
D. Other specialized brachytherapy applications
  • Intra-operative brachytherapy
  • Use of radiation in operating theatre
  • Useful for incomplete surgical removal of cancer
  • Allows highly topical application of radiation
  • If surgery is followed by radiotherapy, one is
    10Gy ahead in tumor dose

43
Intra-operative brachytherapy
  • In practice not often used because
  • not always possible to predict if radiation will
    be needed during the operation
  • requires radiation oncologist to be available
  • radiation safety issues
  • shielded theatre costly
  • patient must be left alone during irradiation
  • even if less than 5min this is a risk due to
    anesthetics

44
A note on radiation protection
  • Many specialized brachytherapy applications are
    performed outside of a conventional radiotherapy
    department - this requires consideration of
  • training
  • shielding
  • communication
  • Excellent planning and documentation is required

45
Intra-operative brachytherapy
  • In principle possible
  • Treatment units (must be HDR) available
  • Applicators are available

46
Summary I
  • Brachytherapy is a highly customized and flexible
    treatment modality
  • Quality of treatment depends on operator skills
  • From a radiation protection point of view remote
    afterloading is most desirable A variety of
    equipment is available to deliver remote
    afterloading brachytherapy
  • HDR brachytherapy is the most common delivery
    mode nowadays.

47
Summary II
  • 125-I seed implants are a alternative for
    radiotherapy of early prostate cancer
  • Endovascular brachytherapy is one of an
    increasing number of non-oncological applications
    of brachytherapy
  • There may be radiation safety issues if
    specialized brachytherapy procedures are
    performed outside of a radiotherapy department as
    staff not used to working with ionizing radiation
    is using radioisotopes

48
References
  • Nath et al. Intravascular brachytherapy physics.
    AAPM TG60 report. Med. Phys. 26 (1999) 119-152
  • Waksman R and Serray P Handbook of vascular
    brachytherapy (London Martin Dunitz) 1998

49
Any questions?
50
Question
  • Please list some radiation safety issues when
    using 90-Sr/Y applicators for ophthalmic
    treatments - you should consider the appendices
    of BSS to classify them...

51
Radiation Safety Issues when using 90-Sr/Y
applicators
  • Occupational exposure
  • cleaning
  • sterilization
  • contamination
  • handling of sources by non-radiotherapy staff

52
Radiation Safety Issues when using 90-Sr/Y
applicators
  • Medical exposure
  • dosimetry difficult
  • contamination from damaged applicator
  • over/under exposure of the eye of the patient
  • irradiation of other areas of the patient

53
Radiation Safety Issues when using 90-Sr/Y
applicators
  • Public exposure
  • transport of the sources
  • security of sources
  • storage and disposal

54
Acknowledgement
  • Craig Lewis, London Regional Cancer Centre
  • Mamoon Haque, RPA Hospital
Write a Comment
User Comments (0)
About PowerShow.com